Skip to content

Study · Animal study (in vivo) · mouse · 1999

7 results

Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide.

Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, Brenneman DE, Gozes I

Journal of neurochemistry1 Mar 1999Cited by 320 (Europe PMC)

PMID10037502 (opens in a new tab)DOI10.1046/j.1471-4159.1999.0721283.x (opens in a new tab)PepBankPUB-10037502
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In newborn apolipoprotein E-deficient mice, daily NAPVSIPQ injections accelerated acquisition of developmental reflexes.

    In plain wordsIn mice lacking apolipoprotein E, daily NAPVSIPQ injections accelerated development of reflexes.

    Peptide
    Davunetide
    Outcome
    IncreaseAcquisition of developmental reflexes
    Study

    mousen: not reported in source

    Newborn apolipoprotein E-deficient mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · injectionAs given in this study (mouse).

    Source sentences

    Summary
    Daily NAPVSIPQ injections to newborn apolipoprotein E-deficient mice accelerated the acquisition of developmental reflexes and prevented short-term memory deficits.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In newborn apolipoprotein E-deficient mice, daily NAPVSIPQ injections prevented short-term memory deficits.

    In plain wordsIn mice lacking apolipoprotein E, daily NAPVSIPQ injections prevented short-term memory problems.

    Peptide
    Davunetide
    Outcome
    DecreaseShort-term memory deficits
    Study

    mousen: not reported in source

    Newborn apolipoprotein E-deficient mice
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · injectionAs given in this study (mouse).

    Source sentences

    Summary
    Daily NAPVSIPQ injections to newborn apolipoprotein E-deficient mice accelerated the acquisition of developmental reflexes and prevented short-term memory deficits.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In the apolipoprotein E-deficiency model, comparative studies suggested greater efficacy of NAPVSIPQ than other neuroprotective peptides.

    In plain wordsIn mice lacking apolipoprotein E, comparisons suggested that NAPVSIPQ was more effective than other neuroprotective peptides.

    Peptide
    Davunetide
    Outcome
    IncreaseComparative neuroprotective efficacy
    Study

    mousen: not reported in source

    Apolipoprotein E-deficiency model
    Comparator
    Other neuroprotective peptides
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Comparative studies suggested that NAPVSIPQ was more efficacious than other neuroprotective peptides in the apolipoprotein E-deficiency model.
  4. 04LabIn vitro (cells)Efficacy outcome

    In mixed neuron-astrocyte cultures, NAPVSIPQ protected against tetrodotoxin toxicity.

    In plain wordsIn cells, NAPVSIPQ protected neurons against tetrodotoxin toxicity.

    Peptide
    Davunetide
    Outcome
    IncreaseProtection against tetrodotoxin toxicity
    Study

    n: not reported in source

    Mixed neuron-astrocyte cultures
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    subfemtomolar concentrationsAs given in this study.

    Source sentences

    Summary
    In mixed neuron-astrocyte cultures, NAPVSIPQ provided neuroprotection at subfemtomolar concentrations against toxicity associated with tetrodotoxin (electrical blockade),
  5. 05LabIn vitro (cells)Efficacy outcome

    In mixed neuron-astrocyte cultures, NAPVSIPQ protected against beta-amyloid toxicity.

    In plain wordsIn cells, NAPVSIPQ protected neurons against beta-amyloid toxicity.

    Peptide
    Davunetide
    Outcome
    IncreaseProtection against beta-amyloid toxicity
    Study

    n: not reported in source

    Mixed neuron-astrocyte cultures
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    subfemtomolar concentrationsAs given in this study.

    Source sentences

    Summary
    In mixed neuron-astrocyte cultures, NAPVSIPQ provided neuroprotection at subfemtomolar concentrations against toxicity associated with tetrodotoxin (electrical blockade), the beta-amyloid peptide (the Alzheimer's disease neurotoxin), N-methyl-D-aspartate (excitotoxicity), and the human immunodeficie…
  6. 06LabIn vitro (cells)Efficacy outcome

    In mixed neuron-astrocyte cultures, NAPVSIPQ protected against N-methyl-D-aspartate excitotoxicity.

    In plain wordsIn cells, NAPVSIPQ protected neurons against N-methyl-D-aspartate toxicity.

    Peptide
    Davunetide
    Outcome
    IncreaseProtection against excitotoxicity
    Study

    n: not reported in source

    Mixed neuron-astrocyte cultures
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    subfemtomolar concentrationsAs given in this study.

    Source sentences

    Summary
    In mixed neuron-astrocyte cultures, NAPVSIPQ provided neuroprotection at subfemtomolar concentrations against toxicity associated with tetrodotoxin (electrical blockade), the beta-amyloid peptide (the Alzheimer's disease neurotoxin), N-methyl-D-aspartate (excitotoxicity), and the human immunodeficie…
  7. 07LabIn vitro (cells)Efficacy outcome

    In mixed neuron-astrocyte cultures, NAPVSIPQ protected against human immunodeficiency virus envelope protein toxicity.

    In plain wordsIn cells, NAPVSIPQ protected neurons against toxicity from the human immunodeficiency virus envelope protein.

    Peptide
    Davunetide
    Outcome
    IncreaseProtection against HIV envelope protein toxicity
    Study

    n: not reported in source

    Mixed neuron-astrocyte cultures
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    subfemtomolar concentrationsAs given in this study.

    Source sentences

    Summary
    In mixed neuron-astrocyte cultures, NAPVSIPQ provided neuroprotection at subfemtomolar concentrations against toxicity associated with tetrodotoxin (electrical blockade), the beta-amyloid peptide (the Alzheimer's disease neurotoxin), N-methyl-D-aspartate (excitotoxicity), and the human immunodeficie…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01056965

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

University of California, San Franciscon = 12Jan 2010 to Dec 2012

Predicted Tauopathies, Including · Progressive Supranuclear Palsy · Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17 · Corticobasal Degeneration Syndrome · Progressive Nonfluent Aphasia

Trial pageClinicalTrials.govUpdated 5 Apr 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.